Watch Ticker

Cardiff Oncology, Inc. Common Stock

Go to Cardiff Oncology, Inc. Common Stock Website

$2.49

-0.15 (-5.68%)

Live

Previous Close

$2.64

Day Range

$2.46 - $2.69

Previous Day Range

$2.3901 - $2.79

Market Cap

$175.6 million USD

Day Vol.

3.0 million

Previous Day Vol.

5.9 million

Currency

USD

Primary Exchange

Nasdaq

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical pr...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Prnewswire - Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

Related tickers: ONCY, EXEL, CRDF, ALXO, VSTM.

Read Full Article

Globe Newswire - Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology, a clinical-stage biotechnology company, announced the pricing of a $40 million underwritten offering of its common stock. The company plans to use the proceeds to fund clinical trials for its lead asset, onvansertib, in metastatic colorectal cancer and pancreatic cancer.

Related tickers: CRDF.

Read Full Article

Trending Tickers

Please sign in to view